Elion Therapeutics is a biotechnology company focused on developing novel antifungals that target high-priority fungal pathogens and address critical unmet needs in antifungal efficacy and safety.
Investors 1
| Date | Name | Website |
| - | AMR Action... | amractionf... |
Mentions in press and media 3
| Date | Title | Description |
| 17.06.2024 | Elion Therapeutics Closes $81 Million Series B Funding Round Led by Deerfield Management and AMR Action Fund | - Funds to support the advancement of SF001, a next-generation polyene antifungal designed for reduced toxicity NEW YORK, June 17, 2024 /PRNewswire/ -- Elion Therapeutics ("Elion", formerly Sfunga Therapeutics), a biotechnology co... |
| 17.06.2024 | Elion Therapeutics Closes $81M Series B Funding Round | Elion Therapeutics, a NYC-based biotechnology company dedicated to advancing the treatment of life-threatening invasive fungal infections (IFIs), closed a $81M Series B funding. The round was led by Deerfield Management and the AMR Action F... |
| - | Elion Therapeutics | “Elion Therapeutics – Transforming the treatment of invasive fungal infections.” |